Shares of Jamf Holding Corp. (BATS:JAMF – Get Rating) have been given an average recommendation of “Buy” by the eleven brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $46.89.
JAMF has been the subject of several research reports. Piper Sandler reduced their target price on Jamf from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Wednesday, March 2nd. Zacks Investment Research raised Jamf from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 12th. Craig Hallum lowered their price target on Jamf from $47.00 to $41.00 in a research report on Wednesday, March 2nd. Barclays cut their price objective on shares of Jamf from $46.00 to $37.00 in a report on Wednesday, January 12th. Finally, Royal Bank of Canada raised their price target on shares of Jamf from $45.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, March 2nd.
JAMF stock opened at $27.35 on Monday. The firm has a 50 day moving average price of $33.22 and a 200-day moving average price of $35.04.
In related news, CFO Jill Putman sold 1,300 shares of Jamf stock in a transaction on Monday, March 7th. The shares were sold at an average price of $33.10, for a total value of $43,030.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jason Wudi sold 6,647 shares of the company’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $35.10, for a total transaction of $233,309.70. Following the sale, the insider now owns 343,961 shares of the company’s stock, valued at $12,073,031.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,414 shares of company stock worth $2,314,064.
Hedge funds and other institutional investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System grew its position in shares of Jamf by 20.4% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 27,306 shares of the company’s stock worth $951,000 after buying an additional 4,630 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Jamf by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 1,331,654 shares of the company’s stock worth $46,355,000 after purchasing an additional 340,533 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of Jamf by 33.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 11,102 shares of the company’s stock valued at $386,000 after purchasing an additional 2,759 shares in the last quarter. Mount Yale Investment Advisors LLC purchased a new position in shares of Jamf during the first quarter valued at about $207,000. Finally, SG Americas Securities LLC bought a new position in Jamf in the first quarter worth about $3,709,000.
Jamf Company Profile (Get Rating)
Jamf Holding Corp. offers a cloud software platform for Apple infrastructure and security platform worldwide. Its products include Jamf Pro, an Apple ecosystem management software solution for IT environments; Jamf Now, a pay-as-you-go Apple device management software solution for small-to-medium-sized businesses; Jamf School, a software solution for educators; Jamf Data Policy, a solution to enforce acceptable usage policies to eliminate shadow IT and block risky content and manage data consumption with real-time analytics and granular reporting; and Jamf Connect that streamlines Mac authentication and identity management; and Jamf Private Access, a ZTNA solution that replaces legacy conditional access and VPN technology.
- Get a free copy of the StockNews.com research report on Jamf (JAMF)
- Skechers Stock Can Be Bought on Pullbacks
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
Receive News & Ratings for Jamf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jamf and related companies with MarketBeat.com's FREE daily email newsletter.